M&A / Deals Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B BioSpaceWhile peptides are currently the dominant approach to GLP-1 agonism, Ambrosia Biosciences is pursuing a small-molecule approach.M&A / DealsMetabolic & GLP-1Read full story pharminent April 1, 2026 (Last updated: April 1, 2026) BioSpace While peptides are currently the dominant approach to GLP-1 agonism, Ambrosia Biosciences is pursuing a small-molecule approach. M&A / DealsMetabolic & GLP-1Read full story Post navigation Previous: FDA Ties Amgen’s Rare Inflammatory Disease Drug to Eight Deaths, Dozens of Liver InjuriesNext: Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
